All Drug and Alcohol Tests

This page brings together all drug and alcohol testing options so you can match the right test window to your testing goal—whether that’s immediate status, recent use, long-term pattern, adherence, or abstinence. A proactive plan uses a screen-then-confirm approach: fast immunoassay screens for broad classes, followed by definitive confirmation with LC-MS/MS or GC-MS when results are non-negative or policy requires it.

Choose the specimen matrix that fits your need: blood (now), oral fluid (very recent), urine (recent/clearance), or hair(weeks–months pattern). Alcohol-specific biomarkers (e.g., BACEtG/EtSPEthCDT) and supportive liver markers add context. Lab results help document use, adherence, and trends; they do not prove impairment, intent, exact dose, or exact timing. Always interpret with a qualified professional and follow your program’s policy.

Signs, Situations & Related Needs

  • Workplace & safety: pre-employment, random, reasonable suspicion, post-incident, return-to-duty

  • Clinical care: pain-management adherence, medication-assisted treatment (MAT), unexpected behaviors, potential interactions

  • Treatment & recovery: abstinence documentation, relapse monitoring, counseling support

  • Legal/compliance: court or custody orders, probation requirements, monitoring agreements

  • When to seek urgent care: suspected overdose, severe sedation, chest pain, suicidal ideation, or signs of alcohol poisoning (confusion, vomiting, slow/irregular breathing)
    All testing should be reviewed by a clinician, Medical Review Officer (MRO), or program administrator.

Why These Tests Matter

What testing can do

  • Verify presence or absence of target substances and confirm specific drugs/metabolites

  • Distinguish adherence vs. non-adherence and identify undisclosed use

  • Provide objective trends to guide frequency of visits, counseling, or program steps

What testing cannot do

  • Prove impairment, exact dose, or time since use

  • Replace clinical judgment, chain-of-custody, or policy requirements

  • Explain motive or context without additional information

What These Tests Measure (at a glance)

Alcohol

  • BAC (blood alcohol concentration): alcohol now; hours-long window. Use: fitness/incident assessments. Caveat:declines rapidly—timing is critical.

  • Urine Ethanol: very short window (hours). Use: very recent consumption.

  • Urine EtG/EtS (ethyl glucuronide/sulfate): detects recent use after alcohol clears (typically 1–3 days, longer with heavy use). Caveat: low positives can follow incidental exposure; labs use cutoffs.

  • PEth (phosphatidylethanol, whole blood): repeated/significant drinking over ~2–4 weeksUse: pattern/relapse monitoring.

  • CDT (carbohydrate-deficient transferrin): supports sustained heavy use (weeks).

  • GGT, AST/ALT, MCV: indirect, not specific—clinical context only.

Drugs of Abuse / Controlled Medications

  • Opioids & semisynthetics: morphine, codeine, 6-MAM (heroin), hydrocodone/hydromorphone, oxycodone/oxymorphone, fentanyl/norfentanyl, methadone/EDDP, buprenorphine/norbuprenorphine.
    Use: adherence in pain/MAT; undisclosed opioid exposure; metabolite patterns verify biotransformation.*

  • Stimulants: amphetamine/methamphetamine (± D/L isomer), MDMA/MDA, methylphenidate metabolites.
    Use: clarify screen cross-reactivity; confirm specific stimulant.*

  • Cocaine: benzoylecgonine (definitive exposure).

  • Cannabinoids: THC-COOH (urine), parent THC (blood/oral fluid).
    Use: matrix determines “recent vs residual” context.*

  • Benzodiazepines: alprazolam/α-hydroxyalprazolam, clonazepam/7-aminoclonazepam, lorazepam, oxazepam, temazepam.
    Note: many are glucuronidated—best detected by LC-MS/MS.*

  • Other classes as ordered: barbiturates, PCP, synthetic opioids/novel psychoactives.

Specimen Validity (Urine)

  • Creatinine, specific gravity, pH, oxidants/nitrites to detect dilution, substitution, or adulteration.

Typical Detection Windows (approximate; depend on dose, frequency, matrix, and cutoff)

  • Blood: hours to ~1 day (current presence)

  • Oral fluid: hours to ~1–2 days (very recent)

  • Urine: ~1–3 days for many drugs; longer for THC with frequent use

  • Hair: weeks–months (long-term pattern; not impairment)

How the Testing Process Works

  1. Define goal & window: “now” (blood/oral fluid), “recent” (urine/oral fluid), or “pattern” (hair; PEth for alcohol).

  2. Select matrix & panel: choose urine/oral fluid/blood/hair and drug classes per policy.

  3. Screen, then confirm: immunoassay screen first; LC-MS/MS or GC-MS confirmation for non-negative or policy-directed classes.

  4. Add validity (urine): creatinine, specific gravity, pH, oxidants to assess dilution/adulteration.

  5. Report & review: secure results list analytes, metabolites, levels (and validity metrics). Compare with medication list, timing, and program rules.

  6. Trend over time: repeat on a set schedule to document abstinence, adherence, or change.

Interpreting Results (General Guidance)

  • Confirmed positive: analyte(s) at/above cutoff—review metabolite profile (e.g., norfentanyl for fentanyl, 6-MAMfor heroin) and prescriptions.

  • Negative/below cutoff: not detected or under threshold—does not exclude use outside the window.

  • Alcohol markers: BAC = current alcohol; EtG/EtS = recent exposure; PEth/CDT = repeated/heavy use; liver enzymes are supportive, not specific.

  • Matrix matters: oral fluid/blood indicate recent use; urine shows clearance; hair shows long-term pattern.
    Always interpret with clinical findings, timing, and policy.

Choosing Panels vs. Individual Tests

  • Abstinence/recovery: EtG/EtS for recent alcohol; PEth (and/or CDT) for patterns; multi-drug panels with confirmation as needed.

  • Workplace/safety programs: standard multi-drug screens with confirmation and chain-of-custody; include urine specimen validity.

  • Pain management/MAT: targeted opioid ± benzodiazepine panels with key metabolites (EDDPnorbuprenorphine).

  • Long-term pattern review: hair panels; pair with periodic urine/oral fluid for near-term checks.

  • Unexpected screen results: expand to definitive LC-MS/MS confirmation; consider isomer testing for amphetamines.

FAQs

What’s the difference between a screen and a confirmation test?
A screen is a quick yes/no immunoassay; confirmation uses mass spectrometry to precisely identify and quantify drugs/metabolites.

Does a positive result prove impairment?
No. It shows presence above a cutoff, not impairment or exact timing.

Which specimen should I choose?
Match the window to the goalblood (now), oral fluid (recent), urine (recent/clearance), hair (weeks–months).

Can prescriptions cause a positive screen?
Yes. That’s why confirmation distinguishes cross-reactivity from true positives.

How do I check alcohol over weeks, not hours?
Use PEth for repeated/heavy use patterns; EtG/EtS detects recent use after alcohol has cleared.

How do I detect nicotine use?
Cotinine is the primary marker; some programs add anabasine to help distinguish tobacco from nicotine replacement.

Internal Links & Cross-References

  • Drug & Alcohol Tests Hub

  • Alcohol

  • Drug Monitoring

  • Drug Confirmation Test

  • Drug Toxicology Monitoring

  • Nicotine & Tobacco

  • Pain Management

  • KEY LAB TESTS: BAC • EtG/EtS • PEth • CDT • Multi-Drug Screen (Urine/Oral Fluid) • LC-MS/MS Drug Confirmation • Hair Drug Panel • Cotinine • Specimen Validity Panel

References

  1. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug and alcohol testing guidance and cutoffs.

  2. U.S. Department of Transportation (DOT). Drug and alcohol testing program regulations.

  3. American Society of Addiction Medicine (ASAM). Appropriate use of drug testing in clinical addiction medicine.

  4. American Association for Clinical Chemistry (AACC). Definitive toxicology testing best practices (LC/GC-MS).

  5. College of American Pathologists (CAP). Toxicology standards and chain-of-custody considerations.

  6. Centers for Disease Control and Prevention (CDC). Alcohol and tobacco biomarkers—public health considerations.

  7. World Health Organization (WHO). Screening and laboratory testing principles for alcohol and drug use.

  8. ARUP Consult/clinical toxicology compendia. Detection windows, metabolite interpretation, and specimen validity.

Available Tests & Panels

Your All Drug & Alcohol Tests menu is pre-populated in the Ulta Lab Tests system. Use filters by goal and window: choose BAC for immediate status, EtG/EtS for recent alcohol use, PEth/CDT for patterns, and multi-drug screens with LC/GC-MS confirmation for definitive results. Include specimen validity for urine when needed, and review all results with your clinician, MRO, or program administrator.

  • Page
  • 2
  • of
  • 9
  • Total Rows
  • 204
Name Matches

The Cardio IQ™ HDL Cholesterol Test evaluates levels of high-density lipoprotein cholesterol, the “good” cholesterol that plays a critical role in heart health. Adequate HDL supports the removal of excess cholesterol from the bloodstream, reducing plaque buildup in arteries. This test provides valuable insight into cardiovascular wellness, lipid balance, and overall risk of heart disease when combined with other lipid panel results.

Blood
Blood Draw

Most Popular

The CEA Test measures carcinoembryonic antigen levels in blood, a protein that may be elevated in certain cancers, especially colorectal, pancreatic, lung, breast, or ovarian cancer. It is not used alone for diagnosis but helps monitor cancer treatment, detect recurrence, and track disease progression. Elevated CEA can also occur in noncancerous conditions. Doctors use this test to support therapy decisions and provide insight into cancer management.

Blood
Blood Draw
Also Known As: Carcinoembryonic Antigen Test

Blood
Blood Draw

The HDL Cholesterol Test measures high-density lipoprotein cholesterol, often called “good” cholesterol, which helps remove excess cholesterol from the bloodstream. Higher HDL levels are linked to a lower risk of heart disease, while low levels may increase cardiovascular risk. Doctors use this blood test as part of a lipid panel to assess heart health, evaluate risk factors, and guide lifestyle or treatment strategies for cardiovascular disease prevention.

Blood
Blood Draw
Also Known As: Good Cholesterol Test

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

The Complete Blood Count with Differential and Platelets Test is a comprehensive blood test that checks red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. The differential analyzes types of white blood cells to detect infections, anemia, clotting abnormalities, immune conditions, and certain cancers. This essential test is often ordered for routine health exams, diagnosis, and monitoring treatment progress.

Blood
Blood Draw
Also Known As: CBC Test, CBC with Differential and Platelets Test, CBC w/Diff and Platelets Test, Full Blood Count Test, Complete Blood Count Test

The Comprehensive Metabolic Panel (CMP) Test measures 21 markers to assess metabolic health, liver and kidney function, and electrolyte balance. It includes glucose, calcium, sodium, potassium, chloride, CO2, albumin, globulin, A/G ratio, total protein, bilirubin, ALP, AST, ALT, BUN, creatinine, BUN/creatinine ratio, and eGFR. The CMP helps detect diabetes, liver or kidney disease, and supports routine screening and chronic condition monitoring.

Blood
Blood Draw
Also Known As: CMP Test, Chemistry Panel Test, Chem Test, Chem 21 Test, Chem 14 Test 

Blood
Blood Draw

Blood
Blood Draw

The Cyclosporine A Trough LCMSMS Blood Test measures the lowest concentration of cyclosporine in the bloodstream before the next dose, providing precise monitoring of immunosuppressive therapy. This test helps evaluate drug absorption, metabolism, and therapeutic levels to prevent organ rejection, minimize toxicity, and support optimal dosing in transplant and autoimmune management.

Blood
Blood Draw

The Dexamethasone Suppression Test measures how cortisol levels respond after dexamethasone administration, assessing feedback within the hypothalamic-pituitary-adrenal (HPA) axis. Lack of suppression may indicate Cushing’s syndrome, pituitary adenoma, or adrenal disease. This test supports evaluation of metabolic disturbances such as obesity, hypertension, or glucose intolerance, offering valuable insight into endocrine balance and adrenal-pituitary function.

Blood
Blood Draw

Blood
Blood Draw

The Digoxin Test evaluates concentration of digoxin in the bloodstream to help monitor therapy for heart failure and irregular heart rhythms. It ensures medication remains in the therapeutic range, preventing toxicity or reduced effectiveness. By measuring drug levels, this test supports safe cardiac management, assessment of arrhythmias, and ongoing cardiovascular health monitoring.

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

Blood
Blood Draw

The Flunitrazepam and Metabolites Quantitative Urine Test measures flunitrazepam, a benzodiazepine, and its metabolites to evaluate drug exposure and metabolism. This test is often used in forensic, clinical, or compliance settings to confirm recent ingestion and monitor misuse. By quantifying parent drug and metabolites, it provides reliable evidence of exposure and supports assessment of benzodiazepine-related effects.

Urine
Urine Collection

Blood
Blood Draw